|
|
Volumn 19, Issue 3, 2008, Pages 831-835
|
|
Phase I trial of PC-Spes2 in advanced hormone refractory prostate cancer
a
|
|
Author keywords
Alternative therapy; Drug trial; Hormone refractory prostate cancer; PC Spes
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANTINEOPLASTIC AGENT;
PC SPES 2;
PROSTATE SPECIFIC ANTIGEN;
UNCLASSIFIED DRUG;
ADULT;
AGED;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BLOOD CLOTTING DISORDER;
CANCER GROWTH;
CANCER INHIBITION;
CLINICAL ARTICLE;
CLINICAL TRIAL;
DIARRHEA;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG WITHDRAWAL;
GASTROINTESTINAL SYMPTOM;
GLEASON SCORE;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
HUMAN;
INTERNATIONAL NORMALIZED RATIO;
MALE;
MASS SPECTROMETRY;
OPEN STUDY;
OVERALL SURVIVAL;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSTATE CANCER;
SIDE EFFECT;
SURVIVAL RATE;
THROMBOEMBOLISM;
TREATMENT DURATION;
TREATMENT OUTCOME;
UNITED KINGDOM;
|
|
EID: 40249108879
PISSN: 1021335X
EISSN: None
Source Type: Journal
DOI: 10.3892/or.19.3.831 Document Type: Article |
|
Times cited : (18)
|
|
References (17)
|
